10x Genomics, Inc. — Director's Dealing 2022

Sep 16, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2022-09-14

Reporting Person: McAnear Justin J. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-14	Class A Common Stock	A	20297	—	Acquired	78389	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-14	Stock Option (right to buy)	$33.67	A	40593	Acquired	2032-09-14	Class A Common Stock (40593)	Direct
2022-09-14	Performance-based Restricted Stock Units	$	A	40593	Acquired	2026-09-14	Class A Common Stock (40593)	Direct

Footnotes

F1: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/16th of the RSUs vest on each quarterly anniversary measured from August 21, 2022, subject to the Reporting Person continuing as a service provider through each such date.

F2: 1/48th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2022, subject to the Reporting Person continuing as a service provider through each such date.

F3: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the PSUs vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date.